Gastroenterology & Hepatology

EmailEmail    |   Bookmark Page Bookmark  |   RSS Feeds RSS  |   Print Page Print  

Clinical Trials
 

  • A 5-Year Non-interventional Registry Study of Humira (Adalimumab) in Patients With Moderately to Severely Active Crohn's Disease (CD)- Protocol P06-134. Status: Ongoing ~ Follow up. Principal Investigator: Lilani Perera, MD

  • SECURE: A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia®) for Crohn's Disease.  Status: Ongoing ~ Enrolling. Principal  Investigator: Lilani Perera, MD                                                             

  • C13008: A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease. Status: Ongoing ~ Follow up. Principal Investigator: Lilani Perera, MD

  • CCX114157: A 52 week Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of SK1605786A in the Maintenance of Remission in Subjects with Crohn's Disease. Status: Ongoing ~ Enrolling. Principal Investigator: Lilani Perera, MD

  • CCX114643: A Randomized, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with SK1605786A in Subjects with Moderately-to-Severely Active Crohn’s Disease. Status: Ongoing ~ Enrolling. Principal Investigator: Lilani Perera, MD

  • CCX114644: An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn’s Disease. Status: Ongoing ~ Enrolling. Principal Investigator: Lilani Perera, MD

  • Protocol VX11-222-106: A Multicenter, Open-Label, Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, and Ribavirin) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis. Status: Ongoing ~ Follow up. Principal Investigator: Jose Franco, MD

  • HALO Patient Registry: Ablation of Barrett's Esophagus. Status: Ongoing ~ Follow up. Principal Investigator: Kulwinder Dua, MD

  • The IRAP Registry is a multi-center prospective, collaborative database designed to create a national registry that collects information concerning episodes of Idiopathic Recurrent Acute Pancreatitis from Pancreatitis Centers. Status: Ongoing ~ Follow up. Principal Investigator: Kulwinder Dua, MD

  • RFIB3053 {PRO00017742}: A study to assess repeat treatment efficacy and safety of Rifaximin 550 MG TID in subjects with Irritable Bowel Syndrome with Diarrhea (IBS-D). Status: Approved. Principal Investigator: Reza Shaker, MD

 

 

 

webmaster@mcw.edu
© 2014 Medical College of Wisconsin
Page Updated 02/24/2014